Search

Your search keyword '"Souverein, Patrick C."' showing total 1,107 results
Start Over Author "Souverein, Patrick C." Search Limiters Academic (Peer-Reviewed) Journals
1,107 results on '"Souverein, Patrick C."'

4. Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study

Author

Morrow, Richard L., Mintzes, Barbara, Souverein, Patrick C., Hallgreen, Christine E., Ahmed, Bilal, Roughead, Elizabeth E., De Bruin, Marie L., Kristiansen, Sarah Brøgger, Lexchin, Joel, Kemp-Casey, Anna, Sketris, Ingrid, Mangin, Dee, Pearson, Sallie-Anne, Puil, Lorri, Lopert, Ruth, Bero, Lisa, Gnjidic, Danijela, Sarpatwari, Ameet, and Dormuth, Colin R.

Published
2022
Full Text
View/download PDF

7. The association of type 2 diabetes‐related characteristics with fracture risk at different sites.

Author

van Hulten, Veerle, Souverein, Patrick C., Starup‐Linde, Jakob, Viggers, Rikke, Klungel, Olaf H., Vestergaard, Peter, Brouwers, Martijn C. J. G., van den Bergh, Joop P., and Driessen, Johanna H. M.

Subjects
*TYPE 2 diabetes, *GLYCEMIC control, *HUMERAL fractures, *SKULL fractures, *HIP fractures, *ANKLE
Abstract

Aim: To determine the association of diabetes‐related characteristics with fractures at different sites in individuals with type 2 diabetes (T2D). Materials and Methods: We conducted a cohort study using the Clinical Practice Research Datalink (CPRD) GOLD. Patients aged over 30 years with T2D were identified within the CPRD. Patients were followed from the start of diabetes treatment until the end of data collection, death, or the occurrence of a fracture. Cox proportional hazards models were used to estimate the hazard ratios for the association of the individual characteristics (diabetes duration, glycated haemoglobin [HbA1c] level, and microvascular complications) with fracture risk, adjusted for demographics, comorbidities and comedication. Results: A diabetes duration of >10 years was associated with an increased risk of any fracture and major osteoporotic fractures (MOFs), while a diabetes duration of >8 years was associated with an increased hip fracture risk, compared to a duration <2 years. An HbA1c level <6% was associated with an increased fracture risk compared to HbA1c values of 6% to <7%. The presence of one or two microvascular complications was associated with an increased risk of any fracture and MOFs and the presence of two microvascular complications was associated with an increased hip fracture risk, compared to no microvascular complications. Conclusion: In conclusion, our study shows that a diabetes duration of 10 years or more, strict glycaemic control resulting in HbA1c levels below 6%, and/or the presence of at least one microvascular complication increased the risk of any fracture, hip fractures, MOFs, and humerus fractures, but not ankle, scapula or skull fractures. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Incretin‐based therapy and the risk of diabetic foot ulcers and related events.

Author

Werkman, Nikki C. C., Driessen, Johanna H. M., Klungel, Olaf H., Schaper, Nicolaas S., Souverein, Patrick C., Stehouwer, Coen D. A., and Nielen, Johannes T. H.

Subjects
DIABETIC foot, LEG amputation, TYPE 2 diabetes, PROPORTIONAL hazards models, PROPENSITY score matching, PEPTIDASE, PEPTIDE receptors
Abstract

Aim: To investigate the effect of dipeptidyl peptidase‐4 inhibitors (DPP4‐Is) and glucagon‐like peptide‐1 receptor agonists (GLP1‐RAs) on diabetic foot ulcer (DFU) and DFU‐related outcomes (lower limb amputation [LLA], DFU‐related hospitalization and mortality). Methods: We performed a cohort study with data from the Clinical Practice Research Datalink Aurum database with linkage to hospital data. We included people with type 2 diabetes starting treatment with metformin. Then we propensity score matched new users of DPP4‐Is and sulphonylureas (N = 98 770), and new users of GLP1‐RAs and insulin (N = 25 422). Cox proportional hazards models estimated the hazard ratios (HRs) for the outcomes. Results: We observed a lower risk of DFU with both DPP4‐I use versus sulphonylurea use (HR 0.88, 95% confidence interval [CI]: 0.79‐0.97) and GLP1‐RA use versus insulin use (HR 0.44, 95% CI: 0.32‐0.60) for short‐term exposure (≤ 400 days) and HR 0.74 (95% CI: 0.60‐0.92) for long‐term exposure (>400 days). Furthermore, the risks of hospitalization and mortality were lower with both DPP4‐I use and GLP1‐RA use. The risk of LLA was lower with GLP1‐RA use. The results remained consistent across several sensitivity analyses. Conclusions: Incretin‐based therapy was associated with a lower risk of DFU and DFU‐related outcomes. This suggests benefits for the use of this treatment in people at risk of DFU. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Fracture patterns and associated risk factors in pediatric and early adulthood type 1 diabetes: Findings from a nationwide retrospective cohort study

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmacoepidemiology, Rasmussen, Nicklas H, Driessen, Johanna H M, Kvist, Annika Vestergaard, Souverein, Patrick C, van den Bergh, Joop P, Vestergaard, Peter, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmacoepidemiology, Rasmussen, Nicklas H, Driessen, Johanna H M, Kvist, Annika Vestergaard, Souverein, Patrick C, van den Bergh, Joop P, and Vestergaard, Peter

Published
2024

10. Fracture patterns in adult onset type 1 diabetes and associated risk factors - A nationwide cohort study

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmacoepidemiology, Rasmussen, Nicklas H, Driessen, Johanna H M, Kvist, Annika Vestergaard, Souverein, Patrick C, van den Bergh, Joop, Vestergaard, Peter, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmacoepidemiology, Rasmussen, Nicklas H, Driessen, Johanna H M, Kvist, Annika Vestergaard, Souverein, Patrick C, van den Bergh, Joop, and Vestergaard, Peter

Published
2024

11. Within-episode repeat antibiotic prescriptions in patients with respiratory tract infections: A population-based cohort study

Author

Afd Pharmacoepi & Clinical Pharmacology, PECP - Centre for Pharmacoepidemiology, Pharmacoepidemiology and Clinical Pharmacology, Lalmohamed, Arief, Venekamp, Roderick P, Bolhuis, Albert, Souverein, Patrick C, van de Wijgert, Janneke H H M, Gulliford, Martin C, Hay, Alastair D, Afd Pharmacoepi & Clinical Pharmacology, PECP - Centre for Pharmacoepidemiology, Pharmacoepidemiology and Clinical Pharmacology, Lalmohamed, Arief, Venekamp, Roderick P, Bolhuis, Albert, Souverein, Patrick C, van de Wijgert, Janneke H H M, Gulliford, Martin C, and Hay, Alastair D

Published
2024

16. Imminent fall risk after fracture

Author

Schene, Merle R, primary, Wyers, Caroline E, additional, Driessen, Annemariek M H, additional, Souverein, Patrick C, additional, Gemmeke, Marle, additional, van den Bergh, Joop P, additional, and Willems, Hanna C, additional

Published
2023
Full Text
View/download PDF

18. Suspected adverse reactions reported for blood, blood components, and blood products in <scp>VigiBase</scp>

Author

Samukange, Washington T, Lu, Ting-An, Souverein, Patrick C, Gardarsdottir, Helga, Mantel-Teeuwisse, Aukje K, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, and Afd Pharmacoepi & Clinical Pharmacology

Subjects
VigiBase, blood safety, haemovigilance, Immunology, Immunology and Allergy, blood products, adverse reactions, Hematology
Abstract

INTRODUCTION: Since being designated as medicines by World Health Organization (WHO), blood components are subject to pharmacovigilance reporting. Using VigiBase, the WHO global database of individual case safety reports (ICSRs), we characterized reports of adverse reactions for all blood products. STUDY DESIGN AND METHODS: ICSRs involving blood products as the suspected medicine in VigiBase between 1968 and 2021 were extracted. MedDRA preferred terms and the International Society of Blood Transfusion haemovigilance definitions were used to stratify adverse reactions. Descriptive statistics were used to characterize ICSR demographics. RESULTS: A total of 111,033 ICSRs containing 577,577 suspected adverse reactions with 6152 MedDRA preferred terms were reported for 34 blood products. There were 12,153 (10.9%) reports for blood components, 98,135 (88.4%) reports for plasma-derived medicines, and 745 (0.7%) reports for recombinant products. The majority of reports (21.0% and 19.7%, respectively) were from patients aged 45-64 and over 65 years. The Americas contributed the most ICSRs (49.7%). Top reported suspected adverse reactions were for the following MedDRA preferred terms: headache (3.5%), pyrexia (2.8%), chills (2.8%), dyspnoea (1.8%), and nausea (1.8%). CONCLUSION: VigiBase already has a large number of reports on blood products. When compared to other existing haemovigilance databases, our study found reports from a broader range of countries and reporters. This may provide us with new perspectives, but for VigiBase to reach its full potential in haemovigilance some alterations in what is captured in reports are required.

Published
2023

19. Exploring the role of low-frequency and rare exonic variants in alcohol and tobacco use

Author

Marees, Andries T., Hammerschlag, Anke R., Bastarache, Lisa, de Kluiver, Hilde, Vorspan, Florence, van den Brink, Wim, Smit, Dirk J., Denys, Damiaan, Gamazon, Eric R., Li-Gao, Ruifang, Breetvelt, Elemi J., de Groot, Mark C.H., Galesloot, Tessel E., Vermeulen, Sita H., Poppelaars, Jan L., Souverein, Patrick C., Keeman, Renske, de Mutsert, Renée, Noordam, Raymond, Rosendaal, Frits R., Stringa, Najada, Mook-Kanamori, Dennis O., Vaartjes, Ilonca, Kiemeney, Lambertus A., den Heijer, Martin, van Schoor, Natasja M., Klungel, Olaf H., Maitland-Van der Zee, Anke H., Schmidt, Marjanka K., Polderman, Tinca J.C., van der Leij, Andries R., Posthuma, Danielle, and Derks, Eske M.

Published
2018
Full Text
View/download PDF

23. The associations of sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors as add‐on to metformin with fracture risk in patients with type 2 diabetes mellitus

Author

van Hulten, Veerle, primary, Driessen, Johanna H. M., additional, Starup‐Linde, Jakob K., additional, Al‐Mashhadi, Zheer K., additional, Viggers, Rikke, additional, Klungel, Olaf H., additional, Souverein, Patrick C., additional, Vestergaard, Peter, additional, Stehouwer, Coen D. A., additional, and van den Bergh, Joop P., additional

Published
2023
Full Text
View/download PDF

24. Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible addition of risk modifiers on top of SCORE2

Author

Hageman, Steven H J, primary, Petitjean, Carmen, additional, Pennells, Lisa, additional, Kaptoge, Stephen, additional, Pajouheshnia, Romin, additional, Tillmann, Taavi, additional, Blaha, Michael J, additional, McClelland, Robyn L, additional, Matsushita, Kunihiro, additional, Nambi, Vijay, additional, Klungel, Olaf H, additional, Souverein, Patrick C, additional, van der Schouw, Yvonne T, additional, Verschuren, W M Monique, additional, Lehmann, Nils, additional, Erbel, Raimund, additional, Jöckel, Karl-Heinz, additional, Di Angelantonio, Emanuele, additional, Visseren, Frank L J, additional, and Dorresteijn, Jannick A N, additional

Published
2023
Full Text
View/download PDF

29. Mapping the risk of infections in patients with multiple sclerosis

Author

Leung, Melissa Wy, Bazelier, Marloes T, Souverein, Patrick C, Uitdehaag, Bernard Mj, Klungel, Olaf H, Leufkens, Hubert Gm, Pajouheshnia, Romin, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Neurology, and Amsterdam Neuroscience - Neuroinfection & -inflammation

Subjects
Multiple Sclerosis, Databases, Factual, Incidence, Clinical Neurology, United Kingdom, United Kingdom Clinical Practice Research Datalink GOLD and Aurum, Neurology, Risk Factors, Multiple sclerosis infections, Humans, Neurology (clinical), multiple outcomes multi-database study, urinary tract infection
Abstract

Background: People with multiple sclerosis (pwMS) have an increased risk of infections; risk factors include underlying disease, physical impairment and use of some disease-modifying treatments. Objective: To quantify changes in population-level infection rates among pwMS and compare these to the general population and people with rheumatoid arthritis (pwRA), and identify patient characteristics predictive of infections after MS diagnosis. Methods: We conducted a multi-database study using data on 23,226 people with MS diagnosis from the UK Clinical Practice Research Datalink Aurum and GOLD (January 2000–December 2020). PwMS were matched to MS-free controls and pwRA. We calculated infection rates, and estimated incidence rate ratios (IRR) and 95% confidence intervals (CI) of predictors for infections ⩽ 5 years after MS diagnosis using Poisson regression. Results: Among pwMS, overall infection rates remained stable – 1.51-fold (1.49–1.52) that in MS-free controls and 0.87-fold (0.86–0.88) that in pwRA – although urinary tract infection rate per 1000 person-years increased from 98.7 (96.1–101) (2000–2010) to 136 (134–138) (2011–2020). Recent infection before MS diagnosis was most predictive of infections (1 infection: IRR 1.92 (1.86–1.97); ⩾2 infections: IRR 3.00 (2.89–3.10)). Conclusion: The population-level elevated risk of infection among pwMS has remained stable despite the introduction of disease-modifying treatments.

Published
2022

30. Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible addition of risk modifiers on top of SCORE2

Author

Hageman, Steven Hj, Petitjean, Carmen, Pennells, Lisa, Kaptoge, Stephen, Pajouheshnia, Romin, Tillmann, Taavi, Blaha, Michael J, McClelland, Robyn L, Matsushita, Kunihiro, Nambi, Vijay, Klungel, Olaf H, Souverein, Patrick C, van der Schouw, Yvonne T, Verschuren, Wm Monique, Lehmann, Nils, Erbel, Raimund, Jöckel, Karl-Heinz, Di Angelantonio, Emanuele, Visseren, Frank Lj, and Dorresteijn, Jannick An

Published
2023

33. Suspected adverse reactions reported for blood, blood components, and blood products in VigiBase

Author

Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, Samukange, Washington T, Lu, Ting-An, Souverein, Patrick C, Gardarsdottir, Helga, Mantel-Teeuwisse, Aukje K, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, Samukange, Washington T, Lu, Ting-An, Souverein, Patrick C, Gardarsdottir, Helga, and Mantel-Teeuwisse, Aukje K

Published
2023

34. Prescribing of low-dose rivaroxaban in patients with atherosclerotic cardiovascular disease in the United Kingdom and the Netherlands

Author

Hunt, Nicholas B., Pajouheshnia, Romin, Salih, Allan, van Doorn, Sander, Souverein, Patrick C., Bazelier, Marloes T., Klungel, Olaf H., Gardarsdottir, Helga, Hunt, Nicholas B., Pajouheshnia, Romin, Salih, Allan, van Doorn, Sander, Souverein, Patrick C., Bazelier, Marloes T., Klungel, Olaf H., and Gardarsdottir, Helga

Abstract

Aims Low-dose rivaroxaban has been indicated for the management of atherosclerotic cardiovascular disease (ASCVD) after recent (2019-2020) updates to European guidelines. We aimed to describe prescription trends of low-dose rivaroxaban in ASCVD patients over the period 2015-2022 in two European countries, to compare the trends before and after guideline changes, and to determine the characteristics of users. Methods In a cross-sectional interrupted time series analysis, utilization of low-dose rivaroxaban (2.5 mg, twice daily) was measured in Clinical Practice Research Datalink Aurum (United Kingdom [UK]) and the PHARMO Database Network (the Netherlands) from 1 January 2015 to 28 February 2022 in patients with an ASCVD diagnosis. Incidence rates (IRs) and incidence rate ratios (IRRs) of new use (within 182 days) compared to the reference period, 2015-2018, were calculated. Age, sex and comorbidities of users were compared to those of nonusers. Results In the UK, from 721 271 eligible subjects the IR of new use of low-dose rivaroxaban in the period 2015-2018, before guideline changes, was 12.4 per 100 000 person-years and after guideline changes in 2020-2022 was 124.0 (IRR 10.0, 95% confidence interval [CI] 8.5, 11.8). In the Netherlands from 394 851 subjects, the IR in 2015-2018 was 2.4 per 100 000 person-years and in 2020 was 16.3 (IRR 6.7, 95% CI 4.0, 11.4). Users were younger (UK mean difference [MD] −6.1 years, Netherlands −2.4 years; P < .05) and more likely to be male (UK difference 11.5%, Netherlands 13.4%; P < .001) than nonusers. Conclusions There was a statistically significant increase in the use of low-dose rivaroxaban for the management of ASCVD after guideline changes in the UK and the Netherlands. There were international differences, but low-dose rivaroxaban has not been put into widespread practice.

Published
2023
Full Text
View/download PDF

35. Cross-Regional Data Initiative for the Assessment and Development of Treatment for Neurological and Mental Disorders

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmacoepidemiology, Tsai, Daniel Hsiang-Te, Bell, J Simon, Abtahi, Shahab, Baak, Brenda N, Bazelier, Marloes T, Brauer, Ruth, Chan, Adrienne Y L, Chan, Esther W, Chen, Haoqian, Chui, Celine S L, Cook, Sharon, Crystal, Stephen, Gandhi, Poonam, Hartikainen, Sirpa, Ho, Frederick K, Hsu, Shao-Ti, Ilomäki, Jenni, Kim, Ju Hwan, Klungel, Olaf H, Koponen, Marjaana, Lau, Wallis C Y, Lau, Kui Kai, Lum, Terry Y S, Luo, Hao, Man, Kenneth K C, Pell, Jill P, Setoguchi, Soko, Shao, Shih-Chieh, Shen, Chin-Yao, Shin, Ju-Young, Souverein, Patrick C, Tolppanen, Anna-Maija, Wei, Li, Wong, Ian C K, Lai, Edward Chia-Cheng, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmacoepidemiology, Tsai, Daniel Hsiang-Te, Bell, J Simon, Abtahi, Shahab, Baak, Brenda N, Bazelier, Marloes T, Brauer, Ruth, Chan, Adrienne Y L, Chan, Esther W, Chen, Haoqian, Chui, Celine S L, Cook, Sharon, Crystal, Stephen, Gandhi, Poonam, Hartikainen, Sirpa, Ho, Frederick K, Hsu, Shao-Ti, Ilomäki, Jenni, Kim, Ju Hwan, Klungel, Olaf H, Koponen, Marjaana, Lau, Wallis C Y, Lau, Kui Kai, Lum, Terry Y S, Luo, Hao, Man, Kenneth K C, Pell, Jill P, Setoguchi, Soko, Shao, Shih-Chieh, Shen, Chin-Yao, Shin, Ju-Young, Souverein, Patrick C, Tolppanen, Anna-Maija, Wei, Li, Wong, Ian C K, and Lai, Edward Chia-Cheng

Published
2023

36. Imminent fall risk after fracture

Author

Afd Pharmacoepi & Clinical Pharmacology, PECP – Centre for Clinical Therapeutics, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmacoepidemiology, Schene, Merle R., Wyers, Caroline E., Driessen, Annemariek M.H., Souverein, Patrick C., Gemmeke, Marle, Van Den Bergh, Joop P., Willems, Hanna C., Afd Pharmacoepi & Clinical Pharmacology, PECP – Centre for Clinical Therapeutics, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmacoepidemiology, Schene, Merle R., Wyers, Caroline E., Driessen, Annemariek M.H., Souverein, Patrick C., Gemmeke, Marle, Van Den Bergh, Joop P., and Willems, Hanna C.

Published
2023

37. Incidence and individual risk prediction of post-COVID-19 cardiovascular disease in the general population: a multivariable prediction model development and validation study

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmacoepidemiology, la Roi-Teeuw, Hannah M, van Smeden, Maarten, Geersing, Geert-Jan, Klungel, Olaf H, Rutten, Frans H, Souverein, Patrick C, van Doorn, Sander, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmacoepidemiology, la Roi-Teeuw, Hannah M, van Smeden, Maarten, Geersing, Geert-Jan, Klungel, Olaf H, Rutten, Frans H, Souverein, Patrick C, and van Doorn, Sander

Published
2023

38. Predictive Value of SLCO1B1 c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmacoepidemiology, Jansen, Marleen E, Rigter, Tessel, Fleur, Thom M C, Souverein, Patrick C, Verschuren, W M Monique, Vijverberg, Susanne J, Swen, Jesse J, Rodenburg, Wendy, Cornel, Martina C, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmacoepidemiology, Jansen, Marleen E, Rigter, Tessel, Fleur, Thom M C, Souverein, Patrick C, Verschuren, W M Monique, Vijverberg, Susanne J, Swen, Jesse J, Rodenburg, Wendy, and Cornel, Martina C

Published
2023

39. The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus

Author

Sub Gen. Pharmacoepi and Clinical Pharm, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmacoepidemiology, van Hulten, Veerle, Driessen, Johanna H M, Starup-Linde, Jakob K, Al-Mashhadi, Zheer K, Viggers, Rikke, Klungel, Olaf H, Souverein, Patrick C, Vestergaard, Peter, Stehouwer, Coen D A, van den Bergh, Joop P, Sub Gen. Pharmacoepi and Clinical Pharm, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmacoepidemiology, van Hulten, Veerle, Driessen, Johanna H M, Starup-Linde, Jakob K, Al-Mashhadi, Zheer K, Viggers, Rikke, Klungel, Olaf H, Souverein, Patrick C, Vestergaard, Peter, Stehouwer, Coen D A, and van den Bergh, Joop P

Published
2023

40. Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible addition of risk modifiers on top of SCORE2

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmacoepidemiology, Hageman, Steven Hj, Petitjean, Carmen, Pennells, Lisa, Kaptoge, Stephen, Pajouheshnia, Romin, Tillmann, Taavi, Blaha, Michael J, McClelland, Robyn L, Matsushita, Kunihiro, Nambi, Vijay, Klungel, Olaf H, Souverein, Patrick C, van der Schouw, Yvonne T, Verschuren, Wm Monique, Lehmann, Nils, Erbel, Raimund, Jöckel, Karl-Heinz, Di Angelantonio, Emanuele, Visseren, Frank Lj, Dorresteijn, Jannick An, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmacoepidemiology, Hageman, Steven Hj, Petitjean, Carmen, Pennells, Lisa, Kaptoge, Stephen, Pajouheshnia, Romin, Tillmann, Taavi, Blaha, Michael J, McClelland, Robyn L, Matsushita, Kunihiro, Nambi, Vijay, Klungel, Olaf H, Souverein, Patrick C, van der Schouw, Yvonne T, Verschuren, Wm Monique, Lehmann, Nils, Erbel, Raimund, Jöckel, Karl-Heinz, Di Angelantonio, Emanuele, Visseren, Frank Lj, and Dorresteijn, Jannick An

Published
2023

41. Prescribing of low-dose rivaroxaban in patients with atherosclerotic cardiovascular disease in the United Kingdom and the Netherlands

Author

Afd Pharmacoepi & Clinical Pharmacology, Sub Biomol.Mass Spectrometry & Proteom., Pharmacoepidemiology and Clinical Pharmacology, Biomolecular Mass Spectrometry and Proteomics, PECP - Centre for Pharmacoepidemiology, Hunt, Nicholas B, Pajouheshnia, Romin, Salih, Allan, van Doorn, Sander, Souverein, Patrick C, Bazelier, Marloes T, Klungel, Olaf H, Gardarsdottir, Helga, Afd Pharmacoepi & Clinical Pharmacology, Sub Biomol.Mass Spectrometry & Proteom., Pharmacoepidemiology and Clinical Pharmacology, Biomolecular Mass Spectrometry and Proteomics, PECP - Centre for Pharmacoepidemiology, Hunt, Nicholas B, Pajouheshnia, Romin, Salih, Allan, van Doorn, Sander, Souverein, Patrick C, Bazelier, Marloes T, Klungel, Olaf H, and Gardarsdottir, Helga

Published
2023

42. Response to: 'Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: A population-based cohort study' by Gong and Zhang and Lin et al

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmacoepidemiology, Abtahi, Shahab, Driessen, Johanna H.M., Burden, Andrea M., Souverein, Patrick C., Van Den Bergh, Joop P., Boonen, Annelies, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmacoepidemiology, Abtahi, Shahab, Driessen, Johanna H.M., Burden, Andrea M., Souverein, Patrick C., Van Den Bergh, Joop P., and Boonen, Annelies

Published
2023

43. Response to: 'Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study' by Zheng

Author

Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, PECP - Centre for Pharmacoepidemiology, Abtahi, Shahab, Driessen, Johanna H M, Burden, Andrea M, Souverein, Patrick C, van den Bergh, Joop P, van Staa, Tjeerd P, Boonen, Annelies, de Vries, Frank, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, PECP - Centre for Pharmacoepidemiology, Abtahi, Shahab, Driessen, Johanna H M, Burden, Andrea M, Souverein, Patrick C, van den Bergh, Joop P, van Staa, Tjeerd P, Boonen, Annelies, and de Vries, Frank

Published
2023

44. Response to: 'Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study' by Zheng

Author

Abtahi, Shahab, Driessen, Johanna H M, Burden, Andrea M, Souverein, Patrick C, van den Bergh, Joop P, van Staa, Tjeerd P, Boonen, Annelies, de Vries, Frank, Abtahi, Shahab, Driessen, Johanna H M, Burden, Andrea M, Souverein, Patrick C, van den Bergh, Joop P, van Staa, Tjeerd P, Boonen, Annelies, and de Vries, Frank

Published
2023

45. Predictive Value of SLCO1B1 c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users.

Author

Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Cardiometabolic Health, Jansen, Marleen E, Rigter, Tessel, Fleur, Thom M C, Souverein, Patrick C, Verschuren, W M Monique, Vijverberg, Susanne J, Swen, Jesse J, Rodenburg, Wendy, Cornel, Martina C, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Cardiometabolic Health, Jansen, Marleen E, Rigter, Tessel, Fleur, Thom M C, Souverein, Patrick C, Verschuren, W M Monique, Vijverberg, Susanne J, Swen, Jesse J, Rodenburg, Wendy, and Cornel, Martina C

Published
2023

46. Incidence and individual risk prediction of post-COVID-19 cardiovascular disease in the general population: a multivariable prediction model development and validation study

Author

HAG Trombose, Epi Methoden Team 3, Infection & Immunity, Circulatory Health, HAG Hart- Vaatziekten, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, la Roi-Teeuw, Hannah M, van Smeden, Maarten, Geersing, Geert-Jan, Klungel, Olaf H, Rutten, Frans H, Souverein, Patrick C, van Doorn, Sander, HAG Trombose, Epi Methoden Team 3, Infection & Immunity, Circulatory Health, HAG Hart- Vaatziekten, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, la Roi-Teeuw, Hannah M, van Smeden, Maarten, Geersing, Geert-Jan, Klungel, Olaf H, Rutten, Frans H, Souverein, Patrick C, and van Doorn, Sander

Published
2023

47. Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible addition of risk modifiers on top of SCORE2

Author

Interne Geneeskunde Vasculaire, RWE/Causal inference, Cardiovasculaire Epi Team 1, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, MS Interne Geneeskunde, Hageman, Steven Hj, Petitjean, Carmen, Pennells, Lisa, Kaptoge, Stephen, Pajouheshnia, Romin, Tillmann, Taavi, Blaha, Michael J, McClelland, Robyn L, Matsushita, Kunihiro, Nambi, Vijay, Klungel, Olaf H, Souverein, Patrick C, van der Schouw, Yvonne T, Verschuren, Wm Monique, Lehmann, Nils, Erbel, Raimund, Jöckel, Karl-Heinz, Di Angelantonio, Emanuele, Visseren, Frank Lj, Dorresteijn, Jannick An, Interne Geneeskunde Vasculaire, RWE/Causal inference, Cardiovasculaire Epi Team 1, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, MS Interne Geneeskunde, Hageman, Steven Hj, Petitjean, Carmen, Pennells, Lisa, Kaptoge, Stephen, Pajouheshnia, Romin, Tillmann, Taavi, Blaha, Michael J, McClelland, Robyn L, Matsushita, Kunihiro, Nambi, Vijay, Klungel, Olaf H, Souverein, Patrick C, van der Schouw, Yvonne T, Verschuren, Wm Monique, Lehmann, Nils, Erbel, Raimund, Jöckel, Karl-Heinz, Di Angelantonio, Emanuele, Visseren, Frank Lj, and Dorresteijn, Jannick An

Published
2023

48. Imminent fall risk after fracture

Author

Schene, Merle R, Wyers, Caroline E, Driessen, Annemariek M H, Souverein, Patrick C, Gemmeke, Marle, van den Bergh, Joop P, Willems, Hanna C, Schene, Merle R, Wyers, Caroline E, Driessen, Annemariek M H, Souverein, Patrick C, Gemmeke, Marle, van den Bergh, Joop P, and Willems, Hanna C

Abstract

RATIONALE: Adults with a recent fracture have a high imminent risk of a subsequent fracture. We hypothesise that, like subsequent fracture risk, fall risk is also highest immediately after a fracture. This study aims to assess if fall risk is time-dependent in subjects with a recent fracture compared to subjects without a fracture. METHODS: This retrospective matched cohort study used data from the UK Clinical Practice Research Datalink GOLD. All subjects =50 years with a fracture between 1993 and 2015 were identified and matched one-to-one to fracture-free controls based on year of birth, sex and practice. The cumulative incidence and relative risk (RR) of a first fall was calculated at various time intervals, with mortality as competing risk. Subsequently, analyses were stratified according to age, sex and type of index fracture. RESULTS: A total of 624,460 subjects were included; 312,230 subjects with an index fracture, matched to 312,230 fracture-free controls (71% females, mean age 70?±?12, mean follow-up 6.5?±?5 years). The RR of falls was highest in the first year after fracture compared to fracture-free controls; males had a 3-fold and females a 2-fold higher risk. This imminent fall risk was present in all age and fracture types and declined over time. A concurrent imminent fracture and mortality risk were confirmed. CONCLUSION/DISCUSSION: This study demonstrates an imminent fall risk in the first years after a fracture in all age and fracture types. This underlines the need for early fall risk assessment and prevention strategies in 50+ adults with a recent fracture.

Published
2023

49. Predictive Value of c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users

Author

Jansen, Marleen E, Rigter, Tessel, Fleur, Thom M C, Souverein, Patrick C, Verschuren, W M Monique, Vijverberg, Susanne J, Swen, Jesse J, Rodenburg, Wendy, and Cornel, Martina C

Subjects
pharmacogenomics, adverse drug reactions, primary care, screening, statins
Abstract

Pharmacogenomic testing is a method to prevent adverse drug reactions. Pharmacogenomics could be relevant to optimize statin treatment, by identifying patients at high risk for adverse drug reactions. We aim to investigate the clinical validity and utility of pre-emptive pharmacogenomics screening in primary care, with SLCO1B1 c.521T>C as a risk factor for statin-induced adverse drug reactions. The focus was on changes in therapy as a proxy for adverse drug reactions observed in statin-users in a population-based Dutch cohort. In total, 1136 statin users were retrospectively genotyped for the SLCO1B1 c.521T>C polymorphism (rs4149056) and information on their statin dispensing was evaluated as cross-sectional research. Approximately half of the included participants discontinued or switched their statin treatment within three years. In our analyses, we could not confirm an association between the SLCO1B1 c.521T>C genotype and any change in statin therapy or arriving at a stable dose sooner in primary care. To be able to evaluate the predictive values of SLCO1B1 c.521T>C genotype on adverse drug reactions from statins, prospective data collection of actual adverse drug reactions and reasons to change statin treatment should be facilitated.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results